Search results
Results from the WOW.Com Content Network
Estrogen dosages for menopausal hormone therapy; Route/form Estrogen Low Standard High Oral: Estradiol: 0.5–1 mg/day: 1–2 mg/day: 2–4 mg/day Estradiol valerate: 0.5–1 mg/day: 1–2 mg/day: 2–4 mg/day Estradiol acetate: 0.45–0.9 mg/day: 0.9–1.8 mg/day: 1.8–3.6 mg/day Conjugated estrogens: 0.3–0.45 mg/day: 0.625 mg/day: 0.9–1. ...
Estrogen: Oral: 2–10 mg/day Various: Estrogen: Sublingual: 1–8 mg/day Climara [c] Estrogen: TD patch: 25–400 μg/day Divigel [c] Estrogen: TD gel: 0.5–5 mg/day Various: Estrogen: SC implant: 50–200 mg every 6–24 mos Estradiol valerate: Progynova: Estrogen: Oral: 2–10 mg/day Progynova: Estrogen: Sublingual: 1–8 mg/day Delestrogen ...
Trough estradiol levels and MADRS Tooltip Montgomery–Åsberg Depression Rating Scale scores with 1 mg sublingual micronized estradiol 3 to 8 times per day (3 to 8 mg/day total; mean 4.8 mg/day total) in women with postpartum depression. [8] Blood was drawn specifically in the mornings before the first dose of sublingual estradiol for the day. [8]
Estradiol levels with 50 to 100 μg/day transdermal estradiol patches applied to the forearm and to the scrotum in a crossover study in 2 men with prostate cancer. [14] In 35 men treated continuously with one 100 μg/day estradiol patch scrotally, the mean estradiol level was ~500 pg/mL (range ~125–1,200 pg/mL).
Relative oral potencies of estrogens Estrogen HF Tooltip Hot flashes VE Tooltip Vaginal epithelium UCa Tooltip Urinary calcium FSH Tooltip Follicle-stimulating hormone LH Tooltip Luteinizing hormone
Atypical (dual estrogen and nitrogen mustard alkylating antineoplastic): Estramustine phosphate sodium (Emcyt) – 140 mg; Oral estradiol valerate (except in combination with dienogest as an oral contraceptive) is not available in the U.S. and is used primarily in Europe. [2]
Target ranges for hormone levels in hormone therapy for transgender women; Source Place Estradiol, total Testosterone, total Refs Endocrine Society: United States: 100–200 pg/mL <50 ng/dL [1] World Professional Association for Transgender Health (WPATH) United States
[126] [127] [124] Women who are not on a birth control pill or hormone therapy have a risk of VTE of about 1 to 5 out of 10,000 women per year. [126] [127] [116] [124] In women taking a birth control pill containing ethinylestradiol and a progestin, the risk of VTE is in the range of 3 to 10 out of 10,000 women per year.